| Study of Recombinant Influenza Vaccine Containing Different H3 Antigens Without or With Adjuvant in Healthy Adult Subjects (NCT04451954) | Sanofi Pasteur, a Sanofi Company | 2020-07-02 |
| Flublok or Fluzone With Advax-CpG55.2 or AF03 (NCT03945825) | National Institute of Allergy and Infectious Diseases (NIAID) | 2019-06-10 |
| 2017 A/H7N9 IIV Revaccination (NCT03738241) | National Institute of Allergy and Infectious Diseases (NIAID) | 2018-12-18 |
| Safety/Efficacy Study of Seqirus A/H7N9 IIV With or Without MF59(R) Adjuvant to Prevent Avian Influenza (NCT03682120) | National Institute of Allergy and Infectious Diseases (NIAID) | 2018-11-02 |
| Development of Childhood Anti-Influenza Immunity (NCT03673345) | National Institute of Allergy and Infectious Diseases (NIAID) | 2018-09-25 |
| H3N2 M2SR in Pediatric Population (NCT03553940) | National Institute of Allergy and Infectious Diseases (NIAID) | 2018-08-15 |
| H5N1 With or Without Topical Aldara in Healthy Adults (NCT03472976) | National Institute of Allergy and Infectious Diseases (NIAID) | 2018-06-13 |
| Two Doses of Multimeric-001 (M-001) Followed by Influenza Vaccine (NCT03058692) | National Institute of Allergy and Infectious Diseases (NIAID) | 2018-04-09 |
| Co-Administration of AS03 Adjuvanted A/H7N9 IIV With IIV4 (NCT03318315) | National Institute of Allergy and Infectious Diseases (NIAID) | 2018-02-20 |
| Sanofi 2017 H7N9 With/Without AS03 in Adults/Elderly (NCT03312231) | National Institute of Allergy and Infectious Diseases (NIAID) | 2018-02-14 |
| Age and Response to Flu Vaccines (NCT03328325) | National Institute of Allergy and Infectious Diseases (NIAID) | 2017-12-14 |
| Analysis of Bone Marrow and Blood B Cell Immune Responses to Influenza Vaccination (NCT02485639) | National Institute of Allergy and Infectious Diseases (NIAID) | 2015-12-23 |
| Evaluation of Human Immune Responses to Influenza Virus Vaccination in Healthy Volunteers (NCT02385123) | National Institute of Allergy and Infectious Diseases (NIAID) | 2015-04-01 |